The Overall Survival and Safety of Men with Metastatic Hormone-Sensitive Prostate Cancer Treated with Combination Therapy of Novel Androgen Receptor Antagonists and Androgen-Deprivation Therapy: A Systematic Review and Meta-Analysis

Figure 9

Funnel plot of publication bias risk. (a) Overall survival rate, (b) progression-free survival, (c) any adverse event, (d) grade 3 or 4 adverse event, (e) any serious adverse events, and (f) adverse events leading to death.

(a)

(b)

(c)

(d)

(e)

(f)